Recombinant Human VIL Protein，His

VIL (Vascular Inhibitory Protein) is a member of the class of proteins involved in various cellular processes, including angiogenesis and cell adhesion. Research on VIL recombinant proteins has gained prominence due to their potential therapeutic applications in cancer treatment and wound healing. These proteins can modulate the interaction between vascular endothelial cells and the extracellular matrix, thus influencing angiogenesis, which is critical in tumor growth and metastasis. The understanding of VIL’s structure and function at the molecular level allows for the engineering of recombinant versions that may have enhanced biological activities or reduced immunogenicity. Furthermore, VIL-related studies have suggested its role as a biomarker for various diseases, thereby opening avenues for diagnostic applications. The modulation of VIL pathways can provide insights into the development of new anti-angiogenic drugs, which could be pivotal in treating pathological conditions characterized by abnormal blood vessel formation. Additionally, the ability to produce VIL in recombinant systems ensures a consistent supply for research and potential therapeutic use, allowing scientists to explore its mechanistic roles further. Overall, the investigation of VIL recombinant proteins is essential for understanding their biological significance and developing novel therapeutic strategies that could leverage their unique properties in mitigating disease.